

DAFTAR PUSTAKA

- Anonim,. 2011. Quantikine[®] Human Soluble VEGF R2 Immunoassay (Catalog Number DVR200) R&D Systems, Inc, United States of America.
- Amorim TGF., Staub GJ., Lazzarotto C., Silva AV., Manes J., Ferronato MG., Shiozawa MBC., Nasciso-Schiavon JL., Dantas-Correa EB. & Schiavon L., 2012. Validation and compatison of simple noninvasive Models for the prediction of liver fibrosis in chronic hepatitis C. *Ann Hepatol* 11(6): 855-861.
- Anggorowati N., Yoshihiko Yano Y., Heriyanto DS., Rinonce HT., Utsumi T., Mulya DP., Subronto YW. & Yoshitake Hayashi1 Y. 2012. Clinical and Virological Characteristics of Hepatitis B or C Virus Co-Infection With HIV in Indonesian Patients. *J Med Virol* 84:857–865.
- Asmis T., Balaa F., Sculy L., Papadatos D. & Marginean C. 2010. Diagnosis and management of hepatocellular carcinoma: results of a consensus meeting of The Ottawa Hospital Cancer centre. *Curr Oncol* 17(2): 6-12.
- Akiyoshi F., Sata M., Suzuku H., Uchimura Y., Mitsuyama K., Matsuo K. & Tanikawa K. 1998. Serum Vascular Endothelial Growth Factor Levels in Various Liver Diseases. *Digestive Dis Sci* 43(1): 41- 45.
- Aucejo F., Kin R., Zein N., Quintini C., Uso TD., Lopez R., Eghtesad B., Fung J., Miller C. & Yerian L. 2009. Vascular Endothelian Growth Factor Receptor 2 Expression in Non-tumorous Cirrhotic Liver is higher when Hepatoma is beyond Milan Criteria. *Liver Transpl* 15: 169-176.
- Bidwell DE., Buck AA., Diesfeld HJ., Enders B., Haworth J., Huldt G., Kent NH., Kirsten C., Mattern P., Ruitenberg EJ. & Voller A. 1976. The enzyme-linked immunosorbent assay (ELISA). *Bull World Health Organ* 54: 129-139.
- Bocci G., Man S., Green SK., Francia G., Ebos JML., du Manoir JM., Weinerman A., Emmenegger U., Ma L., Thorpe P., Davidoff A., Huber J., Hicklin DJ. & Kerbel RS. 2004. Increased Plasma Vascular Endothelial Growth Factor (VEGF) as Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies. *Cancer* 64: 6616-6625.

- Bradbury PA., Zhai R., Ma C., Xu W., Hopkins J. & Kulke MJ. 2009. Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis. *Clin Cancer Res* 15(14): 4680–4685.
- Brodsky SV., Mendeleev N., Melamed M. & Ramaswamy G. 2007. Vascular Density and VEGF Expression in Hepatic Lesions. *J Gastrointestin Liver Dis* 16(4): 373-377.
- Caldwell S. & Park SH. 2009. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. *J Gastroenterol* 44 (Suppl XIX): 96-101.
- Cébe-Suarez S., Zehnder-Fjällman A. & Ballmer-Hofer K. 2006. The role of VEGF receptors in angiogenesis; complex partnerships. *Cell Mol Life Sci* 63: 601–615.
- Cha C. & DeMatteo RP. 2005. Molecular mechanism in hepatocellular carcinoma development. *Best Pract Res Clin Gastroenterol* 19(1): 25-37.
- Chaiworapongsa T., Romero R., Tarca AL., Kusanovic JP., Gotsch F., Mittal P., Kim SK., Vaisbuch E., Mazaki-Tovi S., Erez O., Dong Z., Kim CJ., Yeo L. & Hassan SS. 2010. A decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsia. *Am J Obstet Gynecol* 202: 550 e1-10.
- Chan HLY., Hui AY., Wong ML., Tse AML., Hung LCT., Wong VWS. & Sung JY. 2004. Genotype C hepatitis B virus infection is associated with on increased risk of hepatocellular carcinoma. *Gut* 53: 1494-1498.
- Chen JA., Shi M., Li JQ. & Qian CN. 2010. Angiogenesis: multiple masks in hepatocellular carcinoma and liver regeneration. *Hepatology* 51: 537-547.
- Chu JS., Jiao GF. & Zhang B. 2013. Expression and prognostic value of VEGFR-2, PDGFR- β , and c-Met in advanced hepatocellular Carcinoma. *J Experimental & Clin Cancer Res* 32 (16). (ISSN: 1756-9966)
- Corpechot C., Barbu V., Wendum D., Kinnman N., Rey C. & Poupon R. 2002. Hypoxia-Induced VEGF and Collagen I Expressions Are Associated With Angiogenesis and Fibrogenesis in Experimental Cirrhosis. *Hepatology* 35: 1010-1021.

- Dahlan MS. 2011. Penelitian Prognostik dan Sistem Skoring: disertai praktik dengan SPSS dan STATA, *Seri Evidence Based Medicine (seri 8)*. Akqa Prisma Interdelta, Jatinangor, Bandung.
- Deli G., Jin CH., Mu R., Yang S., Liang Y., Chen D. & Makuuchi M. 2005 Immunohistochemical assessment of angiogenesis in hepatocellular carcinoma and surrounding cirrhotic liver tissues. *World J Gastroenterol* 11(7): 960-963.
- Dhanasekaran R., Limaye A. & Cabrera R. 2012. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics Hepatic Medicine. *Evidence and Research* 4:19–37.
- Ferlay J., Shin HR., Bray F., Forman MC. & Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 127: 2893–2917.
- Dreys J. & Schneider V. 2006. The use of vascular biomarkers and imaging studies in the early clinical development of anti-tumour agents targeting angiogenesis. *J Int Med* 260: 517–529.
- Duda DG., Ancukiewicz M., Jain RK. 2010. Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers? *J Clin Oncol* 28(2): 183-192.
- Ebos JML., Lee CR., Bogdanovic E., Alami J., Van Slyke P., Francia G. & Xu P. 2008. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. *Cancer Res* 68(2): 521-529.
- El-Assal ON., Yamanoi A., Soda Y., Yamaguchi M., Igarashi M., Yamamoto A., Nabika T. & Nagasue N. 1998. Clinical Significance of Microvessel Density and Vascular Endothelial Growth Factor Expression in Hepatocellular Carcinoma and Surrounding Liver: Possible Involvement of Vascular Endothelial Growth Factor in the Angiogenesis of Cirrhotic Liver. *Hepatology* 27: 1554-1562.
- European Association for the Study of the Liver, 2011, EASL Clinical Practice Guidelines: Management of chronic hepatitis C virus infection. *J Hepatol* 55(2) : 245-264.

- European Association for the Study of the Liver. 2012. EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 57(1):167-185.
- Fatmaa U., Sevilyayd S., Zeynepa G., Gulfera O., Aynurb A., Omerc B., Fuatc E., Sahinc C., Osmanc Y., Ferahe A. & Erdemf A. 2013, APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B. *Eur J Gastroenterol Hepatol* 25(9):1076-1081.
- Fernández M., Semela D., Bruix J., Colle I., Pinzani M. & Bosch J. 2009. Angiogenesis in liver disease. *J Hepatol* 50: 604-620.
- Ferrara N. 2002. Role of Vascular Endothelial Growth Factor in Physiologic and Pathologic Angiogenesis: Therapeutic Implication. *Semin Oncol* 29(6) suppl 16: 10-14.
- Garza-Veloz I., Castruita-De la Rosa C., Coetes-Flores R., Martinez-Gaytan V., Rivera-Muñoz, & Garcia-Mayorga EA. 2011. No association between polymorphisms/ haplotypes of the vascular endothelial growth factors gene and preeclamsia. *BMC Pregnancy Childbirth* 11:35.
- Giatromanolaki A., Kotsiou S., Koukourakis MI. & Sivridis E. 2007. Angiogenic Factor Expression in Hepatic Cirrhosis. *Mediators inflamm*, 4 halaman, (Article ID 67187; ISSN 1466-1861).
- Goldberg E. & Chopra S. 2009. Overview of the complications, prognosis, and management of cirrhosis. *UpToDate* 18.2.
- Gomaa AW., Khan SA., Toledano MB., Waked I. & Taylor-Robinson SD. 2008. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis, *World J Gastroenterol* 14(27): 4300-4308.
- Gomaa AI., Khan SA., Leen ELS., Waked I. & Taylor-Robinson SD. 2009. Diagnosis of hepatocellular carcinoma. *World J Gastroenterol* 15(11): 1301-1314.
- Guan X., Zhao H., Niu J., Tang D., Ajani JA. & Wei Q. 2009. The *VEGF* -634G>C promoter polymorphism is associated with risk of gastric cancer. *BMC Gastroenterology* 9:77 (doi:10,1186/1471-230X-9-77).

- Guo RP., Zhong C., Shi M., Zhang CQ., Wei W., Zhang YQ. & Li JQ. 2006. Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma. *J Cancer Res Clin Oncol* 132: 547-555.
- Hanrahan EO., Lin HY., Kim ES., Yan S., Du DZ. & McKee KS. 2009. Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer. *J Clin Oncol* 28:193-201.
- Han YF., Zhao J., Ma LY., Yin JH., Chang WJ., Zhang HW. & Cao GW. 2011. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. *World J Gastroenterol* 14; 17(38): 4258-4270.
- Hartono B. 2008. *Profil Kesehatan Indonesia 2007*, In Susilo K., Hary P., Hasnawati., Rahmani B (eds). Departemen Kesehatan RI, Jakarta.
- Helaly GF. & Shamaa LAA. 2006. Influence of Hepatitis C Virus infection on Circulating Levels of sICAM-1 and VEGF in Patients with Hepatitis C and Hepatocellular Carcinoma (HCC) and Their Role in Enhancing Detection of HCC. *Egyptian J Immunol* 13(1): 27-38.
- Heriyanto DS., Yano Y., Utsumi T., Anggorowati N., Rinonce HT., Lusida MI., Soetjpto., Triwikatmani C, Ratnasari N., Maduseno S., Purnama PB., Nurdjanah S. & Hayashi Y. 2012. Mutations Within Enhancer II and BCP Regions of Hepatitis B Virus in Relation to Advanced Liver Diseases in Patients Infected With Subgenotype B3 in Indonesia. *J Med Virol* 84:44-51.
- Hwang EW. & Cheung R. 2011. Global Epidemiology of Hepatitis B Virus (HBV) Infection. *NA J Med Sci* 4(1):7-13.
- Jantus-Lewintre E., Sanmartin E., Sirera R., Blasco A. & Sanchez JJ. 2011. Combined VEGF-A and VEGFR-2 concentration in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC. *Lung Cancer* 74: 326-331.
- Jain L., Vargo CA., Danesi R., Sissung TM., Price DK., Venzon D., Venitz J. & Figg WD. 2009. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. *Mol Cancer Ther*; 8(9): 2496-2508.

- Jianjun Z., Jingqun H., Jianqiang C., Xiaojie Y. & Zhihua Y. 2003. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. *Chin Med J* 116(5): 772-776.
- ^aJuniastuti., Utsumi T., Aksono EB., Yano Y., Soejipto., Hayashi Y., Hotta H., Ratam FA., Kusumobroto HO. & Lusida MI. 2013. Predominance of precore mutations and clinical significance of basal core promoter mutations in chronic hepatitis B virus infection in Indonesia. *Biomedical Reports* 1: 522-528.
- ^bJuniastuti., Wibowo BP., Wibawa IDN., Utsumi T., Mustika S., Amin M., Wahyuni RM., Kurniawan H., Hendrayana A., Setiawan PB., Yamani LN., Soetjipto., Yano Y., Hotta H., Hayashi Y. & Lusida MI. 2014. Interleukin-28B Polymorphisms and Response of Chronic Hepatitis C Patients from Indonesia to Pegylated Interferon/Ribavirin Treatment. *J Clin Microbiol* 52(6): 2193–2195 .
- Karoui S1., Ben-Romdhane S., Serghini M., Ben-Mustapha N., Boubaker J., Haouet S. & Filali A. 2012. Is APRI score a suitable tool for prediction of fibrosis in Tunisian patients with genotype 1 chronic viral hepatitis C? *Tunis Med*, 90(4):282-5.
- ^aKarp G. 2010. The Path to Gene Expression. *Cell Biology* sixth edition International Student Version. John Wiley & Sons Inc. Printed in Singapore : 157-164.
- ^bKarp G. 2010. Methods in Cell Biology. *Cell Biology* sixth edition International Student Version. John Wiley & Sons Inc. Printed in Singapore : 734-740.
- Kaseb AO., Hanbali A., Cotant M., Hassan MM., Wollner I. & Philip PA. 2009. Vascular Endothelial Growth Factor in the Management of Hepatocellular Carcinoma. *Cancer* 115: 4895-4906.
- Kazimi MC., Nalbantoglu S., Kilic M. & Berdeli A. 2010. Clinical and genetic aspects of Turkish hepatocellular carcinoma patients: Results of single center study. *Int J Phyl Sci* 5(15): 2379-2392.
- Kew MC. 1997. Hepatitis Viruses and Human Hepatocellular Carcinoma. *Yale J Biology Med* 70: 119-125.

- Kim JG., Chae YS., Sohn SK., Cho YY., Moon JH., Park JY., Jeon SW., Lee IT., Choi GS. & Jun SH. 2008. Vascular Endothelial Growth Factor Gene Polymorphisms Associated with Prognosis for Patients with Colorectal Cancer. *Clin Cancer Res* 14(1): 62-66.
- Kong SY., Park JW., Lee JA., Park JE., Park KW., Hong EK. & Kim CM. 2007. Association Between Vascular Endothelial Growth Factor Gene Polymorphisms and survival in Hepatocellular Carcinoma Patients. *Hepatology* 46: 446-455.
- Korpany G., Sullivan LA., Smyth E., Carney DN. & Brekken RA. 2010. Molecular and Clinical Aspects of Targeting the VEGF Pathway in Tumors. *J Oncol* 12 halaman. (Article ID 652320; doi:10.1155/2010/652320)
- Kramer MF. & Coen DM. 2001. Enzymatic Amplification of DNA by PCR: Standard Procedures and Optimization. *Curr Prot Mol Biology*: 15.1.1-15.1.14
- Kudo M., Chung H. & Osaki Y. 2003. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). *J Gastroenterol* 38:207-215.
- Lai WK. & Adams DH. 2005. Angiogenesis and chronic inflammation; the potential for novel therapeutic approaches in chronic liver disease. *J Hepatol* 42: 7-11.
- Lauer GM., Walker B. 2001. Hepatitis C virus infection. *N Engl J Med* 345(1) : 41-52.
- Lavanchy D. 2004. Hepatitis B Virus Epidemiology, Disease Burden, Treatment, and Current and Emerging Prevention and Control Measures. *J Viral Hepat* 11(2).
- Lavarone M., Lampertico P., Iannuzzi F., Manenti E., Donato MF., Arosio E., Bertolini F., Primignani M., Sangiovanni A. & Colombo M. 2007. Increased Expression of Vascular Endothelial Growth Factor in Small Hepatocellular Carcinoma. *J Viral Hepat* 14(2): 133-139.

- Lemeshow S., Hosmer Jr, DW., Klar J. & Lwanga SK. 1997. *Adequacy of sample size in health studies*. Terjemahan dalam bahasa Indonesia oleh Pramono Diby. Gadjah Mada University Press. Yogyakarta.
- Leppänen VM., Prota AE., Jeltsch M., Anisimov A., Kalkkinen N., Strandin, T., Lankinen H., Goldman A., Ballmer-Hofer K. & Alitalo K. 2010. Structural determinants of growth factors binding and specificity by VEGF receptor 2. *PNAS* 107(6): 2425-2430.
- Lesmana CRA., Salim S., Hasan I., Sulaiman AS., Gani RA., Pakasi LA., Lesmana LA., Krisnuhoni E. & Budihusodo U. 2011. Diagnostic Accuracy of Transient Elastography (FibroScan) versus the Aspartate Transaminase to Platelet Ratio Index in Assessing Liver Fibrosis in Chronic Hepatitis B. The Role in Primary Care Setting. *J Clin Pathol* 64(10):916-920.
- Liaw YF., Kao JH., Piratvisuth T., Chan HLY. & Chien RN. 2012. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. *Hepatol Int* 6(3): 531-561.
- ^aLiu Q., Li Y., Zhao J., Sun DL., Duan YN., Wang N., Zhou RM. & Kang S. 2009. Association of polymorphisms -1154G/A and -2578C/A in the vascular endothelial growth factor gene with decreased risk of endometriosis in Chinese women. *Human Repro* 24(10): 2660-2666.
- ^bLiu TT., Yi CS., Chou ASB., Lee MC., Chen MC., Wang LY., Lin HH. & Hu CT. 2009. Comparison Between the CLIP and Okuda Staging Systems for Prediction of survival Time of Patients with Hepatocellular Carcinoma in Eastern Taiwan. *Tsu Chi Med J* 21(1): 34-39.
- Liu L., Zeng F., Wang K., Huang J., Xin L. & Zhu PQ. 2011. Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies. *J Cancer Res Clin Oncol* 137(6):1027-1036.
- Lok ASF. 2007. Navigating the Maze of Hepatitis B Treatments. *Gastroenterol* 132:1586-1594.
- Marrero JA. 2010. Epidemiology of hepatocellular carcinoma and cholangiocarcinoma. In: Hero K. Hussain, Isaac R. Francis : *Primary Carcinomas of the liver*. Cambridge University Press.

- Metzker ML. 2010. Sequencing technologies the next generation. *Genetics* 11: 31-46.
- McMahon G. 2000. VEGF Receptor Signaling in Tumor Angiogenesis. *Oncologist* 5(suppl 1): 3-10.
- McMahon BJ. 2009. The Natural History of Chronic Hepatitis B Virus Infection. *Hepatology* 49: S45-S55.
- Medina J., Arroyo AG., Sánchez-Madrid F. & Moreno-Otero R. 2004. Angiogenesis in Chronic Inflammatory Liver Disease. *Hepatology* 39: 1185-1195.
- Méndez-Sánchez N., Vásquez-Fernández F., Zamora-Valdés D. & Uribe M. 2008. Sorafenib, a systemic therapy for hepatocellular carcinoma. *Ann Hepatol* 7(1): 46-51.
- Murakami Y., Saigo K., Takashima H., Minami M., Okanoué T., Bre´chot C. & Paterlini-Bre´chot P. 2005. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. *Gut* 54:1162–1168,.
- Mokdad AA., Lopez AD., Shahrzaz S., Lozano R., Mokdad AH., Stanaway J., Murray CJL. & Naghavi M. 2014. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. *BMC Medicine* 12:145.
- Moons KGM., Royston P., Vergouwe Y., Grobbee DE. & Altman DG. 2009. Research Methods & Reporting. Prognosis and prognostic research: what, why, and how? *BMJ* 338: 1317-1320.
- Nanashima N., Taura N., Abo T., Ichikawa T., Sakamoto I., Nagayasu T. & Nakao K. 2011. Tumor Marker Levels Before and After Curative Treatment of Hepatocellular Carcinoma as Predictors of Patient Survival. *Dig Dis Sci* (doi: 10.1007/s10620-011-1796-6)
- Nasimuzzaman M., Waris G., Mikolon D., Stupack DG. & Siddiqui A. 2007. Hepatitis C Virus Stabilizes Hypoxia-Inducible Factor -1 and Stimulates the Synthesis of Vascular Endothelial Growth Factor. *J Vir* 81(19):10249–10257.
- Neufeld G., Cohen T., Genagrinvitch S. & Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J* 12: 9-22.

- Noma H., Funatsu H., Mimura T., Eguchi S., & Hori S. 2011. Soluble Vascular Endothelial Growth Factor Receptor-2 and inflammatory Factors in Macular Edema with Branch Retinal Vein Occlusion. *Am J Ophthalmol* 152: 669-677.
- Nurdjanah S. 2006. Sirosis Hati *dalam:* Aru WS., Bambang S., Idrus A., Marcellus S., Siti S. (eds): *Buku Ajar Ilmu Penyakit Dalam Jilid I*, edisi ke 4. Fakultas Kedokteran Universitas Indonesia. Jakarta: 445-448.
- Ott JJ., Stevens GA., Groeger J. & Wiersma ST. 2012. Global epidemiology of hepatitis B virus infection: New estimates of age-specific HBsAg seroprevalence and endemicity. *Vaccine* 30: 2212–2219.
- Parkin DM. 2006. The global health burden of infection-associated cancers in the year 2002. *Int J Cancer* 118: 3030-3044.
- Peng CY., Chien RN. & Liaw YF. 2012. Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. *J Hepatol* 57(2): 442–450.
- Pircher A., Heidegger I., Gunsilius E. & Hilbe W. 2010. Biomarkers of angiogenesis and their role in clinical oncology. *memo* 3: 27-32.
- Poon D., Anderson BO., Chen LT., Tanaka K., Lau WY., Van Cutsem E., Singh H., Chow WC., Ooi LL., Chow P., Khin MW. & Koo WH. 2009. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. *Lancet Oncol* 10: 1111–1118.
- Poon RTP., Lau C., Pang R., Ng KK., Yuen J. & Fan ST. 2007. High serum Vascular Endothelial Growth Factor Levels Predict Poor Prognosis after Radiofrequency Ablation of Hepatocellular Carcinoma: Importance of Tumor Biomarker in Ablative Therapies. *Ann Surg Oncol* 14(6): 1835-1845.
- Poon RTP., Ng IOL., Lau C. & Zhu LX. 2001. Serum Vascular Endothelial Growth Factor Predicts Venous Invasion in Hepatocellular Carcinoma: A Prospective Study. *Ann Surg* 233(2): 227-235.
- Rinonce HT., Yano Y., Utsumi T., Heriyanto DS., Anggorowati N., Widasari DI., Lusida MI., Soetjipto., Prasanto H., Hotta H. & Hayashi Y. 2013. Hepatitis B and C Virus Infection Among Hemodialysis Patients in Yogyakarta, Indonesia: Prevalence and Molecular Evidence for Nosocomial Transmission. *J Med Virol* 85:1348–1361.

- Rosmorduc O.,Wendum D., Corpechot C., Galy B., Sebbagh N., Raleigh J., Housset C. & Poupon R. 1999. Hepatocellular Hypoxia-Induced Vascular Endothelial Growth Factor Expression and Angiogenesis in Experimental Biliary Cirrhosis. *Am J Pathol* 155:1065–1073.
- Royston P., Moons KGM., Altman DG. & Vergouwe Y. 2009. Research Methods & Reporting, Prognosis and prognostic research: Developing a prognostic model. *BMJ* 338: 1373-1377.
- Salcedo X., Medina J., Sanz-Cameno P., Garcia-Buey L., Martin-Vilchez S. & Moreno-Otero R. 2005. Angiogenesis soluble factors as liver disease markers. *Aliment Pharmacol Ther* 22: 23–30.
- Samela D. & Dufour JF. 2004. Angiogenesis and hepatocellular carcinoma. *J Hepatol* 41: 864-880.
- Sakakura C., Hagiwara A., Taniguchi H., Yamaguchi T., Yamagishi H., Takahashi T., Koyama K., Nakamura Y., Abe T. & Inazawa J. 1999. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparative genomic hybridization. *B J Cancer* 80(12): 2034–2039.
- Sastroasmoro S. & Ismael S. 1995. *Dasar-dasar Metodologi Penelitian Klinis*. Bagian Ilmu Kesehatan Anak FK UI. Jakarta.
- Schalm SW. 2006. Natural History of Chronic Hepatitis B in European Countries. Available at:
<http://archives.niddk.nih.gov/fund/other/hbv2006/05%20schalm%20abstract.pdf>
- Schoenleber SJ., Kurts DM., Talealkar JA., Roberts LR. & Gores GJ. 2009. Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma: systematic review and meta-analysis. *B J Cancer* 100: 1385-1392.
- Seeff BL. 2002. Natural History of Chronic Hepatitis C. *Hepatology* 36:S35-S46.
- Shariff MIF., Cox IJ., Gamaa AI., Khan SA., Gedroyc W. & Tahimylor-Robinson SD. 2009. Worldwide Epidemiology, Risk Factors, Diagnosis and Therapeutics. *Expert Rev Gastroenterol Hepatol* 3(4): 353-367.
- Shendure JA., Porreca GJ. & Church GM. 2008. Overview of DNA Sequencing Strategies. *Current Protocols in Molecular Biology*: 7.1.1-7.1.11.

- Shepard CW., Finelli L. & Alter MJ. 2005. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 5: 558–67.
- Shim JH., Park JW., Kim JH., An M., Kong SY., Nam BH., Choi JI., Kim HB., Lee WJ. & Kim CM. 2008. Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. *Cancer Sci* 99(10):2037-2044.
- Song P., Tang W., Tamura S., Hasegawa K., Sugawara Y., Dong J. & Kokudo N. 2010. The management of hepatocellular carcinoma in Asia: A guideline combining quantitative and qualitative evaluation. *BioScience Trends* 4(6): 283-287.
- Sterling RK., Lissen E., Clumeck N., Sola R., Correa MC., Montaner J., Sulkowski MS., Torriani FJ., Dieterich DT., Thomas DL., Messinger D., Nelson M. & for the APRICOT Clinical Investigators. 2006, Development of a Simple Noninvasive Index to Predict Significant Fibrosis in Patients With HIV/HCV Coinfection. *Hepatology* 43:1317-1325.
- Subramaniam S., Kelley RK. & Venook AP. 2013. A review of hepatocellular carcinoma (HCC) staging systems. *Chin Clin Oncol* 2(4):33.
- Sun HC. & Tang ZY. 2004. Angiogenesis in hepatocellular carcinoma: the retrospectives and prespectives. *J Cancer Res Clin Oncol* 130: 307-319.
- Tamori A., Yamanishi Y., Kawashima S., Kanehisa M., Enomoto M., Tanaka H., Kubo S., Shiomi S. & Nishiguchi S. 2005. Alteration of Gene Expression in Human Hepatocellular Carcinomawith Integrated Hepatitis B Virus DNA. *Clin Cancer Res* 11(16): 5821-5826.
- Teshale E., Lu M., Rupp LB., Holmberg SD., Moorman AC., Spradling P., Vijayadeva V., Boscarino JA., Schmidt MA. & Gordon SC. 2014. APRI and FIB-4 are Good Predictors of the Stage of Liver Fibrosis in Chronic Hepatitis B, The Chronic Hepatitis Cohort Study (CHeCS). *J Viral Hepat* 21(12):917-920.
- Trihono. 2013. *Riset Kesehatan Dasar 2013*. Badan Penelitian dan Pengembangan Kesehatan Kementrian Kesehatan RI.

- Wada H., Satoh N., Kitaoka S., Ono K., Morimoto T., Kawamura T., Nakano T., Fujita M., Kita T., Shimatsu A. & Hasegawa K. 2010. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. *Atherosclerosis* 208: 512-517.
- Wakabayashi K. 2010. ELISA -A to Z from introduction to practice (revised 2010/03/25)(<http://www.labanimal.co.kr/product/AtoZ/ELISA-AtoZ%20E.pdf>)
- Wang BE., Ma WM., Sulaiman A., Noer S., Sumoharjo S., Sumarsidi D., Tandon BN., Nakao K., Mishiro S., Miyakawa Y., Akahane Y. & Suzuki H. 2002. Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. *J Med Virol* 67(3):394-400.
- Wai CT., Greenon JK., Fontana RJ., Kalbfleisch JD., Marrero JA., Conjeevaram HS. & Lok ASF. 2003. A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C. *Hepatology* 38:518-526.
- Wedemeyer H., Dore GJ. & Ward JW. 2015. Estimates on HCV disease burden worldwide – filling the gaps. *JVH* 22 (Suppl, S1): 1–5.
- Weisner R., Edwards E., Freeman R., Harper A., Kim R., Kamath P., Kremers W., Lake J., Howard T., Merion RM., Wolfe RA. & Krom R. (United Network for Organ Sharing Liver Disease Severity Score Committee). 2003. Model for End-Stage Liver Disease (MELD) and Allocation of Donor Livers. *Gastroenterol* 124: 91–96.
- Wong R. & Corley DA. 2008. Racial and Ethnic Variations in Hepatocellular Carcinoma Incidence within the United States. *Am J Med* 121: 525-531.
- Wolf DC. 2011. Cirrhosis. *Emedicine*. Updated September 22. 2011.
- Wu LM., Xie HY., Zhou L., Yang Z., Zhang F. & Zheng SS. 2009. A Single Nucleotide Polymorphism in the Vascular Endothelial Growth Factor Gene Is Associated with Recurrence of Hepatocellular Carcinoma after Transplantation. *Arch Med Res* 40: 565-570.
- Yang JC., Teng CF., Wu FC., Tsai HW., Chuang HC., Tsai TF., Hsu YH., Huang W., Wu LW. & Su IJ. 2009. Enhanced Expression of Vascular Endothelial

- Growth Factor-A in Ground Glass Hepatocytes and Its Implication in Hepatitis B Virus Hepatocarcinogenesis. *Hepatology* 49:1962-1971.
- Yang JD. & Roberts LR. 2010. Hepatocellular Carcinoma: A Global View. *Nat Rev Gastroenterol Hepatol*. CME Released: 07/13/2010 (www.medscape.org).
- Yang ZN. & Poon RT-P. 2008. Vascular Changes in Hepatocellular Carcinoma. *Anat Rec* 291: 721-734.
- Yeung P., Wong DK., Lai CL., Fung J., Seto WK. & Yuen MF. 2011. Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B. *J Inf Dis* 203:646–654.
- Yao DF., Wu XH., Zhu Y., Shi GS., Dong ZZ., Yao DB., Qiu LW. & Meng XY. 2005. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Inf*. 4: 220-226.
- Yao DF., Dong ZZ. & Yao M. 2007. Specific molecular markers in hepatocellular carcinoma. *Hepatobiliary Pancreat Dis Int* 6: 241-247.
- Yoshiji H., Noguchi R., Ikenaka Y., Kaji K., Shirai Y., Aihara Y., Yamao J., Toyohara M., Mitoro A., Sawai M., Yoshida M., Morioko C., Fujimoto M., Uemura M., Kawaratani H., Tsujimoto T. & Fukui H. 2011. Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. *Oncology Letters* 2: 69-73.
- Yuwono T. 2005. *Biologi Molekuler*. Penerbit Erlangga. Jakarta : 93-132.
- Zacharoulis D., Hatzitheofilou C., Athanasiou E. & Zacharoulis S. 2005. Antiangiogenic strategies in hepatocellular carcinoma: current status. *Expert Rev Anticancer Ther* 5(4): 645-656.
- Zhao WH., Ma ZM., Zhou XR., Feng YZ. & Fang BS. 2002. Prediction of recurrence and prognosis in patients with hepatocellular carcinoma after resection by use of CLIP score. *World J Gastroenterol* 8(2): 237-242.
- Zhu AX. 2008. Development of Sorafenib and Other Molecularly Targeted Agents in Hepatocellular Carcinoma. *Cancer* 112 (2): 250-258.
- Zhu AX., Ancukiewicz M., Supko JG., Sahani DV., Blaszkowsky LS., Meyerhardt JA., Abrams TA., McCleary NJ., Bhargava P., Muzikansky A.,

Sheehan S., Regan E., Vasudev E., Knowles M., Fuchs CS., Ryan DP., Jain RK. & Duda DG. 2013. Efficacy, safety, pharmacokinetics and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study. *Clin Cancer Res* 19(6): 1557–1566.

Zindy P., Andrieux L., Bonnier D., Musso O., Langouet S., Campion JP., Turlin B., Clément B. & Thérêt N. 2005. Upregulation of DNA repair genes in active cirrhosis associated with hepatocellular carcinoma. *FEBS Letters* 579: 95–99.